TP53 and neuroblastoma: MYCN-amplified and TP53 wild-type neuroblastoma cell lines show remarkable sensitivities to MDM2 antagonists in vitro (Chen et al., 2015; Van Maerken et al., 2006; Gamble et al., 2012).